Literature DB >> 10887481

The biology of mammary transgenes: five rules.

R D Cardiff1.   

Abstract

The development of hyperplasias, dysplasias, and mammary tumors has been studied extensively in transgenic mice. It is now becoming clear that transgenes activate and participate in oncogenic pathways that govern the events surrounding neoplastic progression in transgenic mice. The oncogenic pathways control mammary growth, development, and neoplastic progression. Some of the key features of transgenic biology can be expressed in the following rules: (1) Mammary development is related to the type and amount of transgene expressed; (2) dysplasias and tumors develop from secondary mutations; (3) the transgenes determine tumor phenotype; (4) transgenes may activate dominant oncogenic pathways; and (5) the oncogenic pathway determines prognosis. The study of the comparative pathology of mammary tumorigenesis in many strains of transgenic mice provides examples of these principles.

Entities:  

Mesh:

Year:  1996        PMID: 10887481     DOI: 10.1007/BF02096303

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  53 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

Review 2.  Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes.

Authors:  P K Pattengale; T A Stewart; A Leder; E Sinn; W Muller; I Tepler; E Schmidt; P Leder
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

3.  Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice.

Authors:  Y Matsui; S A Halter; J T Holt; B L Hogan; R J Coffey
Journal:  Cell       Date:  1990-06-15       Impact factor: 41.582

4.  Cause of failure of lactation in mouse mammary tumor virus/human transforming growth factor alpha transgenic mice.

Authors:  S Sakai; M Mizuno; T Harigaya; K Yamamoto; T Mori; R J Coffey; H Nagasawa
Journal:  Proc Soc Exp Biol Med       Date:  1994-03

5.  Role of endocrine, autocrine, and paracrine interactions in the development of mammary hyperplasia in Wnt-1 transgenic mice.

Authors:  T P Lin; R C Guzman; R C Osborn; G Thordarson; S Nandi
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

6.  PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas.

Authors:  M S Trimble; J H Xin; C T Guy; W J Muller; J A Hassell
Journal:  Oncogene       Date:  1993-11       Impact factor: 9.867

Review 7.  Transgenic models of tumor development.

Authors:  J M Adams; S Cory
Journal:  Science       Date:  1991-11-22       Impact factor: 47.728

8.  Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands.

Authors:  C Jhappan; D Gallahan; C Stahle; E Chu; G H Smith; G Merlino; R Callahan
Journal:  Genes Dev       Date:  1992-03       Impact factor: 11.361

9.  Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene.

Authors:  R J Coffey; K S Meise; Y Matsui; B L Hogan; P J Dempsey; S A Halter
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

10.  Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression.

Authors:  C J Sympson; R S Talhouk; C M Alexander; J R Chin; S M Clift; M J Bissell; Z Werb
Journal:  J Cell Biol       Date:  1994-05       Impact factor: 10.539

View more
  19 in total

Review 1.  Modification and repression of genes expressed in the mammary gland using gene targeting and other technologies.

Authors:  J L Vilotte; P L'Huillier; J C Mercier
Journal:  J Mammary Gland Biol Neoplasia       Date:  1998-07       Impact factor: 2.673

Review 2.  Conditional control of gene expression in the mammary gland.

Authors:  P A Furth
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

Review 3.  Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.

Authors:  K L Carraway; C A Carraway; K L Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 4.  EGF-related peptides and their receptors in mammary gland development.

Authors:  R P DiAugustine; R G Richards; J Sebastian
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 5.  Cell cycle genes in a mouse mammary hyperplasia model.

Authors:  Thenaa K Said; Daniel Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

Review 6.  Folate, DNA methylation, and mouse models of breast tumorigenesis.

Authors:  Joshua W Miller; Alexander D Borowsky; Teresa C Marple; Erik T McGoldrick; Lisa Dillard-Telm; Lawrence J T Young; Ralph Green
Journal:  Nutr Rev       Date:  2008-08       Impact factor: 7.110

7.  Protein kinase CK2: signaling and tumorigenesis in the mammary gland.

Authors:  E Landesman-Bollag; D H Song; R Romieu-Mourez; D J Sussman; R D Cardiff; G E Sonenshein; D C Seldin
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

8.  Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats.

Authors:  B R Davies; A M Platt-Higgins; G Schmidt; P S Rudland
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

Review 9.  Genetically engineered mouse models of mammary intraepithelial neoplasia.

Authors:  R D Cardiff; D Moghanaki; R A Jensen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

Review 10.  The preneoplastic phenotype in murine mammary tumorigenesis.

Authors:  D Medina
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.